1,325 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Philip James Wealth Mangement LLC

Philip James Wealth Mangement LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,325 shares of the biotechnology company’s stock, valued at approximately $475,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Meiji Yasuda Asset Management Co Ltd. lifted its stake in United Therapeutics by 1.6% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock valued at $652,000 after purchasing an additional 33 shares during the last quarter. Toronto Dominion Bank lifted its position in shares of United Therapeutics by 0.8% during the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock valued at $1,441,000 after buying an additional 37 shares during the last quarter. ClariVest Asset Management LLC grew its stake in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares during the period. Benjamin F. Edwards & Company Inc. increased its holdings in United Therapeutics by 14.0% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 42 shares during the last quarter. Finally, First Citizens Bank & Trust Co. raised its stake in United Therapeutics by 1.8% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock valued at $961,000 after acquiring an additional 48 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Trading Up 1.4 %

Shares of United Therapeutics stock traded up $5.60 on Friday, hitting $408.17. 28,373 shares of the company traded hands, compared to its average volume of 462,641. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $410.79. The firm’s 50-day simple moving average is $358.27 and its 200 day simple moving average is $320.94. The company has a market cap of $18.22 billion, a P/E ratio of 17.68, a P/E/G ratio of 1.16 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.38 earnings per share. Analysts predict that United Therapeutics Co. will post 25.1 earnings per share for the current year.

Insiders Place Their Bets

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $344.18, for a total transaction of $1,239,048.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $44,743.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $344.18, for a total transaction of $1,239,048.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $44,743.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $45,293.30. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 81,422 shares of company stock valued at $29,229,828 over the last quarter. 11.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on UTHR. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Bank of America dropped their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research report on Thursday, August 1st. Jefferies Financial Group lifted their price target on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. LADENBURG THALM/SH SH increased their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.